Valuation SCYNEXIS, Inc.

Stocks

Delayed Nasdaq 19:24:11 30/09/2026 +03			5-day change	1st Jan Change
4.905 ^USD	+5.26%		+5.83%	-3.05%

09-28	SCYNEXIS, Inc. Receives Biomedical Advanced Research And Development Authority Contract Providing Up To $214 Million In Non-Dilutive Funding For The Development Of SCY-247	CI
09-22	SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	174	50.94	82.97	45.92	26.54	46.37	-	-
Change	-	-70.72%	62.87%	-44.66%	-42.2%	74.71%	-	-
Enterprise Value (EV)	174	50.94	82.97	45.92	26.54	46.37	46.37	46.37
Change	-	-70.72%	62.87%	-44.66%	-42.2%	74.71%	0%	0%
P/E	-4.88x	-1.06x	1.6x	-2.75x	-3.72x	-1.6x	-2.01x	-2.81x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0.1x	-0x	0x	0.1x	-0x	0.1x	0.1x
Capitalization / Revenue	13.2x	10x	0.59x	12.3x	1.29x	74.8x	6.94x	3.29x
EV / Revenue	0x	0x	0x	0x	0x	74.8x	6.94x	3.29x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	0x	-0x	-0x	-1.15x	-1.87x	-2.02x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-10	-11.76	11.12	-3.52	-1.36	-2.91	-2.315	-1.66
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	13.16	5.091	140.1	3.746	20.6	0.6195	6.677	14.08
EBITDA	-	-85.15	-	-	-	-	-	-
EBIT ¹	-60.84	-85.76	72.67	-37.12	-16.07	-40.32	-24.83	-22.96
Net income ¹	-32.87	-62.81	67.04	-21.29	-8.609	-30.55	-32.43	-22.46
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	48.800	12.480	17.840	9.680	5.059	4.660	4.660	4.660
Nbr of stocks (in thousands)	3,565	4,082	4,651	4,744	5,246	9,950	-	-
Announcement Date	3/29/22 A	3/31/23 A	3/28/24 A	3/12/25 A	3/4/26 A	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
SCYNEXIS, INC.	-1.6x	-	-	-	46.37M
ELI LILLY AND COMPANY	33.68x	12.2x	24.79x	0.59%	1,056B
JOHNSON & JOHNSON	29.76x	6.61x	18.5x	2%	645B
ABBVIE INC.	33.32x	7.79x	16.11x	2.63%	465B
MERCK & CO., INC.	108.6x	6.05x	25.67x	2.29%	368B
ROCHE HOLDING AG	19.01x	4.64x	11.49x	2.87%	335B
NOVARTIS AG	20.51x	5.32x	13.17x	3.01%	275B
ASTRAZENECA PLC	20.92x	4.34x	12.36x	2.04%	255B
AMGEN INC.	26.76x	6.95x	12.37x	2.38%	229B
GILEAD SCIENCES, INC.	-45.76x	6.66x	26x	2.18%	188B
Average	24.52x	6.73x	17.83x	2.22%	381.58B
Weighted average by Cap.	32.80x	7.85x	19.23x	1.9%